Jupiter Neurosciences (JUNS) Free Cash Flow (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Free Cash Flow of -$2.4 million for Q4 2025, up 35.93% year-over-year from -$1.7 million in Q4 2024, and down 105.12% quarter-over-quarter from -$1.2 million in Q3 2025.
Jupiter Neurosciences (JUNS) Free Cash Flow (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Free Cash Flow for 3 consecutive years, with -$2.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Free Cash Flow rose 35.93% year-over-year to -$2.4 million; the TTM figure through Dec 2025 stood at -$5.4 million (down 38.42% YoY), while the FY2025 annual figure was -$5.4 million, down 38.42% from the prior year.
- Free Cash Flow eased to -$2.4 million in Q4 2025 per JUNS's latest filing, from -$1.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$42598.0 in Q3 2024 and bottomed at -$3.7 million in Q4 2024.
- Historically, Free Cash Flow has averaged -$1.1 million across 3 years, with a median of -$828222.0 in 2025.
- On a YoY basis, Free Cash Flow climbed as much as 35.93% in 2025 and fell as far as 2610.1% in 2025.
- Jupiter Neurosciences' Free Cash Flow stood at -$161137.0 in 2023, then plunged by 2193.56% to -$3.7 million in 2024, then surged by 35.93% to -$2.4 million in 2025.
- Business Quant data shows JUNS's Free Cash Flow at -$2.4 million in Q4 2025, -$1.2 million in Q3 2025, and -$828222.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.37 Mn |
| Dec 31, 2025 | -2.37 Mn |
| Sep 30, 2025 | -1.15 Mn |
| Sep 30, 2025 | -1.15 Mn |
| Jun 30, 2025 | -828,222.00 |
| Jun 30, 2025 | -828,222.00 |
| Mar 31, 2025 | -1.06 Mn |
| Mar 31, 2025 | -1.06 Mn |
| Dec 31, 2024 | -3.70 Mn |
| Dec 31, 2024 | -3.70 Mn |
| Sep 30, 2024 | -42,598.00 |
| Sep 30, 2024 | -42,598.00 |
| Jun 30, 2024 | -107,462.00 |
| Jun 30, 2024 | -107,462.00 |
| Mar 31, 2024 | -65,165.00 |
| Mar 31, 2024 | -65,165.00 |
| Dec 31, 2023 | -161,137.00 |
| Dec 31, 2023 | -161,137.00 |